Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

NCT03772587 is registered in ClinicalTrials.gov with Momenta Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03772587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03772587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Lead sponsor
Momenta Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 10, 2019
Completion date
June 25, 2020
Enrollment
68 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis